ZyVersa Therapeutics replaces auditor Marcum LLP with CBIZ CPAs; notes material weaknesses and going concern

ZyVersa Therapeutics, Inc.

Marcum resigned as auditor effective April 4, 2025; CBIZ CPAs engaged April 7 after acquiring Marcum's attest practice.
Marcum's reports for FY2023 and FY2024 included an explanatory paragraph about substantial doubt on the company's ability to continue as a going concern.
Company disclosed material weaknesses in internal control over financial reporting for both FY2023 and FY2024, including lack of segregation of duties.
No disagreements on accounting principles occurred between the company and Marcum during the relevant periods.
Marcum furnished a letter agreeing with the statements; filed as Exhibit 16.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.